



ASX/MEDIA RELEASE

13 September 2017

Helen Kurincic Joins the Sirtex Board as a Non-Executive Director

Sydney, Australia

Sirtex Medical Limited (ASX:SRX) is pleased to announce the appointment of Ms Helen Kurincic as an Independent Non-Executive Director of the Company, effective 13 September, 2017.

Mr Richard Hill, Chairman of Sirtex Medical commented "On behalf of the Sirtex Board, we are delighted that Ms Kurincic has accepted the role as a Non-Executive Director of the Company. She brings substantial healthcare experience to our Board, with an established track record of delivering solid growth to those Companies where she has acted at an executive or board level. Ms Kurincic has precisely the necessary skills and expertise the Company needs to deliver on its strategic plans."

Ms Kurincic has over 20 years of direct executive and board experience within the healthcare industry in Australia. Ms Kurincic is the current Chairman of Integral Diagnostics Limited (ASX:IDX), a diagnostic imaging services provider in Australia that listed on the ASX in 2015; a Non-Executive Director of Estia Health (ASX:EHE), one of the largest residential aged care providers in Australia; a Non-Executive Director of HBF Health Limited, Australia's fourth largest health insurer; and a consultant providing healthcare sector advisory services for global and local investors and research firms.

From 2007 until 2014 Ms Kurincic was the Chief Operating Officer and a Director of Genesis Care from its earliest inception, creating Australia's largest national provider of radiation oncology cancer treatment centres and cardiology services across more than 115 sites.

Prior to that role, she was an Executive Director and CEO of Benetas, one of the leading not-for-profit providers of residential aged care and created a successful in-home care business, in Victoria, Australia; and a Non-Executive Director of DCA Group Limited, a Top 100 ASX listed company and leading provider of diagnostic imaging services in Australia and the United Kingdom and residential aged care in Australia and New Zealand, which was subsequently acquired by CVC Asia Pacific for \$2.7 billion in 2006.

Ms Kurincic holds a Master of Business Administration (MBA) degree from Victorian University and has attended executive education programs at Harvard Business School. Ms Kurincic is a Fellow of the Australian Institute of Company Directors (FAICD).

- ENDS -

About Sirtex Medical, www.sirtex.com

Sirtex Medical Limited (ASX:SRX) is an Australian based medical device company with global market coverage. Its core revenue producing technology, which has regulatory approvals, is a selective internal radiation therapy (SIRT), with clinically proven applications for liver cancer with approximately 80,000 doses supplied and administered over 1,090 medical centres in more than 40 countries.

Head Office
Level 33, 101 Miller Street
North Sydney, NSW 2060
Australia

Americas
300 Unicorn Park Drive
Woburn, MA 01801
United States

Europe, Middle East & Africa
Josef-Schumpeter-Allee 33
53227 Bonn
Germany

Asia Pacific
50 Science Park Road, #01-01
The Kendall Science Park II
Singapore 117406

For further information please contact:

Investor Enquiries:

Mr Richard Hill
Chairman
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8400

Investor/Media Enquiries:

Dr Tom Duthy
Global Investor Relations Manager
Sirtex Medical Limited
Phone: +61 (0) 2 9964 8427
Email: tduthy@sirtex.com

To subscribe to our email alert service for ASX Announcements, please visit:
<http://www.sirtex.com/au/investors/email-alerts/>

Follow us on Twitter: **@sirtexmedical**
Visit us on LinkedIn: **Sirtex Medical Limited**